In the latest trading session, 0.57 million Ventyx Biosciences Inc (NASDAQ:VTYX) shares changed hands as the company’s beta touched 0.52. With the company’s most recent per share price at $1.91 changed hands at -$0.1 or -4.98% at last look, the market valuation stands at $135.06M. VTYX’s current price is a discount, trading about -501.05% off its 52-week high of $11.48. The share price had its 52-week low at $1.67, which suggests the last value was 12.57% up since then. When we look at Ventyx Biosciences Inc’s average trading volume, we note the 10-day average is 1.79 million shares, with the 3-month average coming to 1.81 million.
Analysts gave the Ventyx Biosciences Inc (VTYX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended VTYX as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Ventyx Biosciences Inc’s EPS for the current quarter is expected to be -0.55.
Ventyx Biosciences Inc (NASDAQ:VTYX) trade information
Instantly VTYX was in red as seen in intraday trades today. With action -6.83%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -12.79%, with the 5-day performance at -6.83% in the red. However, in the 30-day time frame, Ventyx Biosciences Inc (NASDAQ:VTYX) is -12.79% down. Looking at the short shares, we see there were 6.68 million shares sold at short interest cover period of 3.5 days.
The consensus price target for the stock as assigned by Wall Street analysts is 45, meaning bulls need an upside of 95.76% from its recent market value. According to analyst projections, VTYX’s forecast low is 6 with 60 as the target high. To hit the forecast high, the stock’s price needs a -3041.36% plunge from its current level, while the stock would need to soar -214.14% for it to hit the projected low.
Ventyx Biosciences Inc (VTYX) estimates and forecasts
Data shows that the Ventyx Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -14.73% over the past 6 months, a 36.67% in annual growth rate that is considerably higher than the industry average of 15.90%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -148.81%. The 2025 estimates are for Ventyx Biosciences Inc earnings to increase by 36.48%, but the outlook for the next 5-year period is at 18.81% per year.
VTYX Dividends
Ventyx Biosciences Inc is expected to release its next quarterly earnings report in March.
Ventyx Biosciences Inc (NASDAQ:VTYX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.49% of Ventyx Biosciences Inc shares while 84.73% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.72%. There are 84.73% institutions holding the Ventyx Biosciences Inc stock share, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) the top institutional holder. As of 2024-06-30, the company held 9.4284% of the shares, roughly 5.83 million VTYX shares worth $13.47 million.
CITADEL ADVISORS LLC holds the second largest percentage of outstanding shares, with 9.3133% or 5.76 million shares worth $13.3 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.78 shares estimated at $3.36 million under it, the former controlled 2.51% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.42% of the shares, roughly 1.71 shares worth around $3.23 million.
